{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:20:59Z","timestamp":1721089259067},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,15]]},"DOI":"10.7759\/cureus.64596","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:30:08Z","timestamp":1721068208000},"source":"Crossref","is-referenced-by-count":0,"title":["Hemophagocytic Lymphohistiocytosis Unmasking Systemic Lupus Erythematosus: Management With Belimumab and a Case Study"],"prefix":"10.7759","author":[{"given":"Anam","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine J","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01182-6","article-title":"Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a translational perspective","volume":"56","author":"Nguyen TT","year":"2024","unstructured":"Nguyen TT, Kim YT, Jeong G, Jin M. Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a translational perspective. Exp Mol Med. 2024, 56:559-69. 10.1038\/s12276-024-01182-6","journal-title":"Exp Mol Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2015.06.008","article-title":"Familial hemophagocytic lymphohistiocytosis","volume":"29","author":"Degar B","year":"2015","unstructured":"Degar B. Familial hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 2015, 29:903-13. 10.1016\/j.hoc.2015.06.008","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00367-1","article-title":"Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management","volume":"22","author":"Henderson LA","year":"2020","unstructured":"Henderson LA, Cron RQ. Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Paediatr Drugs. 2020, 22:29-44. 10.1007\/s40272-019-00367-1","journal-title":"Paediatr Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2016.10.106","article-title":"Association syndrome lymphohystiocytaire (HLH) et lupus syst\u00e9mique: \u00e9tude multicentrique fran\u00e7aise de 103 \u00e9pisodes chez 89 patients adultes [Article in French]","volume":"37","author":"Gavand PE","year":"2016","unstructured":"Gavand PE, Serio I, Larroche C, et al.. Association syndrome lymphohystiocytaire (HLH) et lupus syst\u00e9mique: \u00e9tude multicentrique fran\u00e7aise de 103 \u00e9pisodes chez 89 patients adultes [Article in French]. Rev M\u00e9d Interne. 2016, 37:122-3. 10.1016\/j.revmed.2016.10.106","journal-title":"Rev M\u00e9d Interne"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"26","author":"Ramos-Casals M","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014, 26:1503-16. 10.1016\/S0140-6736(13)61048-X","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy","volume":"34","author":"Griffin G","year":"2020","unstructured":"Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020, 34:101515. 10.1016\/j.berh.2020.101515","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07298.x","article-title":"Early diagnostic and prognostic significance of a specific Th1\/Th2 cytokine pattern in children with haemophagocytic syndrome","volume":"143","author":"Tang Y","year":"2008","unstructured":"Tang Y, Xu X, Song H, et al.. Early diagnostic and prognostic significance of a specific Th1\/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol. 2008, 143:84-91. 10.1111\/j.1365-2141.2008.07298.x","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13779","article-title":"Validation of the HScore and the HLH-2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort","volume":"109","author":"Bilston L","year":"2022","unstructured":"Bilston L, Croden J, Taparia M, Karkhaneh M, Grossman J, Sun HL. Validation of the HScore and the HLH-2004 diagnostic criteria for the diagnosis of hemophagocytic lymphohistiocytosis in a multicenter cohort. Eur J Haematol. 2022, 109:129-37. 10.1111\/ejh.13779","journal-title":"Eur J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186627","article-title":"Bone marrow histomorphological criteria can accurately diagnose hemophagocytic lymphohistiocytosis","volume":"103","author":"Gars E","year":"2018","unstructured":"Gars E, Purington N, Scott G, Chisholm K, Gratzinger D, Martin BA, Ohgami RS. Bone marrow histomorphological criteria can accurately diagnose hemophagocytic lymphohistiocytosis. Haematologica. 2018, 103:1635-41. 10.3324\/haematol.2017.186627","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli F","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, et al.. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020, 382:1811-22. 10.1056\/NEJMoa1911326","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten E","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M, et al.. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017, 130:2728-38. 10.1182\/blood-2017-06-788349","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: A review in systemic lupus erythematosus","volume":"78","author":"Blair HA","year":"2018","unstructured":"Blair HA, Duggan ST. Belimumab: A review in systemic lupus erythematosus. Drugs. 2018, 78:355-66. 10.1007\/s40265-018-0872-z","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta P","year":"2020","unstructured":"Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020, 2:e358-67. 10.1016\/S2665-9913(20)30096-5","journal-title":"Lancet Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23911","article-title":"Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis","volume":"90","author":"Otrock ZK","year":"2015","unstructured":"Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015, 90:220-4. 10.1002\/ajh.23911","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22774","article-title":"Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality","volume":"56","author":"Lin TF","year":"2011","unstructured":"Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011, 56:154-5. 10.1002\/pbc.22774","journal-title":"Pediatr Blood Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/269262-hemophagocytic-lymphohistiocytosis-unmasking-systemic-lupus-erythematosus-management-with-belimumab-and-a-case-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:30:53Z","timestamp":1721068253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/269262-hemophagocytic-lymphohistiocytosis-unmasking-systemic-lupus-erythematosus-management-with-belimumab-and-a-case-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.64596","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}